Modafinil — Eugeroic wakefulness agent (Schedule IV controlled substance)

Armodafinil (R-enantiomer, Nuvigil) has longer half-life (~15h vs ~12h for racemic modafinil) and is FDA-approved for same indications at lower doses (150-250mg). Off-label cognitive enhancement use is widespread but evidence is mixed — controlled studies show benefit in sleep-deprived individuals but minimal benefit in well-rested individuals. Modafinil significantly reduces efficacy of hormonal contraceptives via CYP3A4 induction — important warning for female patients.

Overview

This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.

Compound Class

Eugeroic wakefulness agent (Schedule IV controlled substance)

Mechanism of Action

Precise mechanism incompletely understood but primarily involves dopamine transporter (DAT) inhibition — blocks dopamine reuptake similar to cocaine/amphetamines but with far lower abuse potential and no significant reinforcement. Also inhibits norepinephrine reuptake (NET), increases orexin/hypocretin system activity, and has weak histamine H3 antagonism. The orexin system activation is key to wakefulness maintenance without the jitteriness of amphetamines. Unlike methylphenidate, modafinil produces minimal dopamine flooding in nucleus accumbens (reward circuit) — explaining the lower addiction potential. Schedule IV (low abuse potential vs Schedule II amphetamines).

Regulatory Status

FDA approved (Schedule IV controlled substance) — Provigil 1998

Evidence Level

High — FDA-approved 1998; multiple RCTs across indications; well-established pharmacology